Business & Industry News
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX), announced that it and Mylan Inc. (NYSE: MYL) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension. The Bayer Group once again considerably improved its sales and earnings in 2007
The Bayer Group once again considerably improved its sales and earnings in 2007, and also exceeded its performance targets. "2007 was Bayer's most successful year to date," said Management Board Chairman Werner Wenning on Thursday at the Spring Financial News Conference in Leverkusen. Celebrity Chef Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis
Life and Style Expert Sandra Lee's Semi-Homemade approach to cooking, which involves using 70 percent store-bought items and 30 percent homemade items in every meal, makes life easier for millions of busy Americans. Unknown to most, Lee's signature style was strongly influenced by her grandmother, who suffered from rheumatoid arthritis (RA), a chronic, progressive disease of the immune system that causes joint damage as well as chronic pain, stiffness, swelling and fatigue. AstraZeneca Provides Update On RECENTIN⢠Clinical Development Programme
AstraZeneca today announced that its HORIZON III Phase II/III head-to-head study of RECENTIN™ (cediranib, AZD2171) with chemotherapy versus bevacizumab (Avastin™) with chemotherapy in patients with first line metastatic colorectal cancer (CRC) will be progressing directly into Phase III at 20mg. Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik
Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion. Novartis Vaccines Institute for Global Health (NVGH) is the first institute with nonprofit mission
Novartis announced the opening of a new research institute in Siena with a nonprofit mission to exclusively focus on the development of vaccines for diseases of the developing world. The Novartis Vaccines Institute for Global Health (NVGH) is the first institute of its kind to be set up by a major vaccine manufacturer. More Pharma News ...
Business & Industry
- AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
- CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
- Acquisition of Neogene Therapeutics completed
Research & Development
- Antidepressants used for chronic pain on the rise, but are they effective?
- Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
- Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
- Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
- Power of cancer drugs may see boost by targeting newly ID'd pathway
- A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
- 500,000 missed out on blood pressure lowering drugs during pandemic
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA grants Accelerated Approval for Alzheimer's disease treatment
- FDA approves new HIV drug for adults with limited treatment options
- FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease